Home › Merck Provides Update on Odanacatib Development Program
 

Keywords :   


Merck Provides Update on Odanacatib Development Program

2016-09-02 13:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it is discontinuing the development of odanacatib, Mercks investigational cathepsin K inhibitor for osteoporosis, and will not seek regulatory approval for its use. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Teri Loxam, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: development program update merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.09Eastern North Pacific Tropical Weather Outlook
28.09Atlantic Tropical Weather Outlook
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Public Advisory Number 5
28.09Summary for Tropical Storm Joyce (AT1/AL112024)
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Forecast Discussion Number 5
28.09Tropical Storm Joyce Wind Speed Probabilities Number 5
More »